GlassScriptPhysician profile
Lori A Aaron
NPI 1619387974
$1,672.47
in general payments reported to CMS, 2019-2025
20 companies · $603 in 2025
The $603 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.13 · 2022: $43.87 · 2023: $439 · 2024: $518 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,460 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,460.48 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $294.94 | 2025 | Auvelity |
| Abbvie INC. | $176.82 | 2021-2025 | Vraylar, Ubrelvy |
| Genzyme Corporation | $167.98 | 2023 | |
| Abbott Laboratories | $153.43 | 2024 | Freestyle Libre 3 |
| Kyowa Kirin, INC. | $139.51 | 2023 | |
| Sk Life Science, INC. | $124.10 | 2024 | Xcopri |
| Astellas Pharma US INC | $116.14 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $111.12 | 2024 | Shingrix |
| Astrazeneca Pharmaceuticals LP | $76.02 | 2023-2025 | Breztri, Farxiga |
| Amgen INC. | $68.72 | 2023-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $56.38 | 2022-2025 | Ozempic, Wegovy |
| Eisai INC. | $29.57 | 2024 | |
| Amarin Pharma, INC. | $23.22 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $22.97 | 2024 | Rexulti |
| Pfizer INC. | $22.45 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.11 | 2023 | Synjardy, Jardiance |
| Insmed, INC. | $19.84 | 2025 | Arikayce |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.31 | 2024 | Trulance, Xifaxan |
| Lilly USA, LLC | $16.52 | 2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $15.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Aaron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.